(Thursday, 26 September 2024, Amsterdam, Netherlands) Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages.
This new method, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, uses tumour-specific profiling to detect antibodies unique to stage I and II melanoma patients.
Melanoma, a skin cancer with a high mutation rate, produces immunogenic markers that trigger an immune response, resulting in the production of antibodies against cancer-testis antigens (CTAgs). These CTAgs lead to the production of specific antibodies that can act as early diagnostic and prognostic markers for melanoma.
